East China Medicine Announces Its Controlled Subsidiary Granted IND Approval for DR10624 Injection Targeting Severe Hypertriglyceridemia

Huadong MedicineNotice: Zhejiang Doer Biologics Co., Ltd. (referred to as "Doer Biologics"), a holding subsidiary, has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for DR10624 Injection submitted by Doer Biologics has been approved, allowing the initiation of clinical trials for the indication of hypertriglyceridemia.

(This article is from Yicai)